Drug class
Cardiac glycoside; Na+/K+-ATPase inhibitor
Mechanism of action
Inhibits Na+/K+-ATPase in cardiomyocytes, increasing intracellular sodium and reducing Na+/Ca2+ exchanger activity, thereby increasing intracellular calcium and myocardial contractility. It also increases vagal tone and slows atrioventricular conduction.
General use cases
- Historical treatment of selected heart failure and supraventricular arrhythmias, including atrial fibrillation, in countries where digitoxin remains authorised; narrow therapeutic index requires concentration and clinical monitoring
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
